Overview
Paras Biopharmaceuticals Finland Oy is committed to innovation and high quality products and technology. Paras Biopharmaceuticals Finland Oy has developed robust biosimilars technologies for the following products.
Our technology and biopharma API products cater for the following:
- Osteoporosis
- Rheumatoid Arthritis
- Metabolic Diseases
- Oncology
Paras Biosimilars Technologies / API
Category |
Product/ Biosimilars Technology |
Technology Platform |
| Osteoporosis |
PB Osteo-1010 (Biosimilar) |
Diabrid Technology / NobleCleav® Technology |
| Rheumatoid Arthritis |
PB (RA)- 2010 ( Biosimilar) |
High Expression Technology |
| Metabolic Disorders |
PB (MDT)- 3010 (Biosimilar) |
Diabrid Technology / NobleCleav® Technology |
| Metabolic Disorders |
PB (MDT)- 3020 ( Biosimilar) |
Diabrid Technology / NobleCleav® Technology |
| Metabolic Disorders |
PB (MDT)- 3030 ( Biosimilar) |
High Expression Technology |
| Metabolic Disorders |
PB (MDT)- 3040 ( Biosimilar) |
Diabrid Technology / NobleCleav® Technology |
| Oncology |
PPB (CT)- 4010 |
Under Development |
| Oncology |
PB (CT)- 4020 |
Under Development |
Disclaimer
Products under patents are part of our research projects. These products may be offered only in those countries where patents have expired.
For the latest status, please contact Paras Biopharmaceuticals Finland Oy.
